![]() |
![]() | ![]() |
| We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level. |
Here is another biotech success story: They developed 3-T-C (Epivir) and licensed to Glaxo/Wellcome for 14% royalty. Epivir is an essential 1/3 of the so-called "cocktail" of 3 drugs recently found to have decimating effect on HIV. (See WSJ: 6/14/96, p.1!) This in itself is a great success. The other essential 1/3 is Retrovir (AZT) also from Glaxo/Wellcome. The final 1/3 is a drug made by ABT, MRK, and one other I can't think of offhand. As well, the most powerful of these "protease inhibitors" is nearing FDA approval (or disapproval): AGPH. Another unsung hero. This is the only company I have ever found whose clinical studies have progressed to the point where they have actual hope of creating a drug to treat cryptospiridium (wasting syndrome). And they have a Hepatitis drug in the making. Is anyone else interested in this Canadian company with good tie-ins to the major pharmaceuticals? | ||||||||||||||
|
| Home | Hot | SubjectMarks | PeopleMarks | Keepers | Settings |
| Terms Of Use | Contact Us | Copyright/IP Policy | Privacy Policy | About Us | FAQ | Advertise on SI |
| © 2025 Knight Sac Media. Data provided by Twelve Data, Alpha Vantage, and CityFALCON News |